BridgeBio Pharma (BBIO) Change in Receivables (2024 - 2026)

BridgeBio Pharma has reported Change in Receivables for 3 years, with the latest figure at $65.8 million in Q1 2026.

• Quarterly Change in Receivables fell 40.49% year-over-year to $65.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $90.0 million (up 174.82% YoY) and the FY2025 annual result came in at $134.7 million, up 4434.57% from the prior year.
• Change in Receivables advanced to $65.8 million in Q1 2026 per BBIO's latest filing, from $22.9 million in the prior quarter.
• Over five years, Change in Receivables peaked at $233.7 million in Q1 2024 and troughed at -$234.8 million in Q2 2024.
• A 3-year average of $22.6 million and a median of $22.9 million in 2025 frame the typical range for Change in Receivables.
• The widest YoY moves for Change in Receivables: up 21885.71% in 2025, down 52.71% in 2025.
• Over 3 years, Change in Receivables stood at $4.2 million in 2024, then soared by 440.2% to $22.9 million in 2025, then surged by 186.93% to $65.8 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered $65.8 million, $22.9 million, and $39.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.